#USA #New York #Securities Fraud #Pomerantz LLP #Capricor Therapeutics

Overview

Pomerantz LLP, a law firm renowned for its expertise in corporate and securities litigation, has initiated an investigation concerning potential claims on behalf of investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR). With the pharmaceutical industry continually evolving, legal scrutiny of companies' practices is essential to protect investor interests.

Background

Capricor Therapeutics is a biotechnology company focused on developing therapies for serious, rare diseases. Its investigational cell therapy, deramiocel, aims to treat patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. This unique approach holds significant promise but has drawn attention amid recent events that have altered the company’s market position.

The Investigation

The focus of Pomerantz’s investigation centers around allegations that Capricor, along with certain officers and directors, may have been involved in securities fraud or engaged in other illegal business activities. Investors who believe they have experienced losses due to these practices should contemplate reaching out to the firm for potential participation in a class action.

Recent Developments

On May 5, 2025, the company highlighted a significant milestone by announcing the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA). During this meeting, the FDA confirmed its intent to hold an advisory committee meeting in connection with Capricor's Biologics License Application (BLA) for deramiocel. However, the following day, Capricor's stock witnessed a drastic decline, losing $3.00 or about 29.13% of its value, closing at $7.30 per share.

This alarming drop reflects investor anxiety and speculation surrounding Capricor’s future, especially following further news. On June 20, 2025, an article published by STAT revealed that the new head of the FDA unit responsible had canceled the advisory committee meeting for deramiocel due to uncertainties regarding the drug’s efficacy and safety. This revelation prompted an even steeper decline in Capricor's stock price, plummeting an additional $3.68 or 30.82%, ending the trading day at $8.26 per share.

Legal Implications

The significant downturn in stock value raises serious questions about the integrity of information provided to investors. With Pomerantz taking up the cause for potential plaintiffs, individuals who invested in Capricor now face a critical choice: to stand idly by or to stand up for their rights.

Concerted action may not only be necessary for financial recuperation but could also deliver a powerful message to corporations regarding accountability. As Pomerantz LLP continues its investigation, investors are encouraged to consider participating in legal action, which can play a pivotal role in ensuring that corporate governance standards are maintained.

About Pomerantz LLP

Pomerantz LLP, with offices spread across New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is a well-established firm recognized for its commitment to pursuing justice for clients affected by securities fraud. Established over 85 years ago by Abraham L. Pomerantz, known as the dean of the class action bar, the firm has a distinguished legacy in defending the rights of those wronged by corporate misconduct.

Conclusion

Given the developing situation surrounding Capricor Therapeutics, it’s crucial for affected investors to stay informed and take proactive measures. For further information about joining the class action, investors are advised to contact Danielle Peyton at 646-581-9980, ext. 7980 or via email at [email protected].

The pursuit of justice and accountability remains paramount as investors navigate the turbulent waters of the pharmaceutical industry.

Disclaimer: Previous results do not guarantee similar outcomes.